StockTipsArenaBeta

BUY Privi Speciality Chemicals Limited — Incred Research

BUYPrivi Speciality Chemicals Limited
Privi Speciality Chemicals share price target & all analyst calls

byIncred ResearchHorizon: NA (inferred 1 year)14 Jul 2026via CNBC Awaaz.

Entry₹3,678Inferred
Target₹4,796
Total upside +30.40%
Stop lossNot given
CMP₹3,365.21d ago
Active-8.50%+42.52%upside left 8 mo left
Follow Incred Research for new callsGet alertsWatch PRIVISCL for new buy/sell callsGet alertsSee 7 other Long-term calls on PRIVISCLSee 542 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:27 pm IST
10 supporting6 neutral2 opposing
Supports the BUY call (10)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

4 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·1 Nov · 6d ago

Neutral / worth noting (6)

Outcome of Board Meeting - Financial Results for quarter and half year ended September 30, 2026

BSE · Result·29 Oct · 1w ago

(opens in new tab)

Outcome of the Board Meeting held on October 29, 2026 inter alia to consider & approve Financial Results for quarter and half year ended September 30, 2026 & declaration of first Interim ....

BSE · Board Meeting·29 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (2)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Privi Speciality Chemicals

All analyst calls on Privi Speciality Chemicals

More from Incred Research

Every call and its outcome